A prospective study comparing injectable interferon beta-1a (Rebif 22-44), (Avonex 30) and 1b (Betaseron 250) injection site reaction in multiple sclerosis patients

Background: Multiple sclerosis (MS) is one of the neuroinflammatory disorders that commonly affect the young. Injectable interferons beta-1a (Rebif 22-44, Betaseron 250 and Avonex 30) are one of the most important first line disease modifying therapies with less side effects compared to others. But...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Foziah Jabbar Alshamrani, Hind Alnajashi, Fahad Alkhamis, Ibrahim Alghanimi, Abdulla Alsulaiman, Aishah Albaker, Iqbal bukari, Amir Mohamad
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Electronic Physician 2019-09-01
Edice:	Electronic Physician
Témata:	multiple sclerosis injection site reaction (isr) interferon beta
On-line přístup:	http://www.ephysician.ir/index.php/browse-issues/11/3/1150-7574
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!